You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Krystal Biotech reported $127.3 million in third-quarter VYJUVEK revenue and $63.1 million in net income, ended September 30, 2026 with $1.2 billion in cash and investments, and authorized a share repurchase program of up to $400 million.
Krystal Biotech reported VYJUVEK product revenue, net of $127.3 million for the three months ended September 30, 2026, versus $97.8 million, with a 94% gross margin. Nine-month product revenue, net was $362.9 million, and cumulative revenue since 2023 reached $1,093.3 million.
Krystal Biotech reported that KB113 regressed over 80% of assessed basal cell carcinoma lesions in three Gorlin syndrome patients, with 83.1% overall regression, and was generally well tolerated. The company is discussing advanced clinical development with the FDA.
